Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Production of the State of the Art Therapeutic Radiopharmaceuticals in Iran, From Beta- to Alpha-Emitting Targeted Radionuclide Therapy: Clinical Advances and Perspectives Publisher



Jafari E1 ; Assadi M1 ; Eftekhari M2
Authors
Show Affiliations
Authors Affiliations
  1. 1. The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, Iran
  2. 2. Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Iranian Journal of Nuclear Medicine Published:2024


Abstract

[No abstract available]
Related Docs
1. A Convolutional Neural Network–Based System for Fully Automatic Segmentation of Whole-Body [68Ga]Ga-Psma Pet Images in Prostate Cancer, European Journal of Nuclear Medicine and Molecular Imaging (2024)
2. An Impressive Approach in Nuclear Medicine: Theranostics, PET Clinics (2021)
3. Historical Review of Pharmacological Development and Dosimetry of Psma-Based Theranostics for Prostate Cancer, Journal of Radioanalytical and Nuclear Chemistry (2019)
4. Factors Predicting Biochemical Response and Survival Benefits Following Radioligand Therapy With [177Lu]Lu-Psma in Metastatic Castrate-Resistant Prostate Cancer: A Review, European Journal of Nuclear Medicine and Molecular Imaging (2021)
5. Targeted Radioligand Therapy: Physics and Biology, Internal Dosimetry and Other Practical Aspects During 177Lu/225Ac Treatment in Neuroendocrine Tumors and Metastatic Prostate Cancer, Theranostics (2025)
6. Radiomics and Artificial Intelligence in Radiotheranostics: A Review of Applications for Radioligands Targeting Somatostatin Receptors and Prostate-Specific Membrane Antigens, Diagnostics (2024)
7. Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain, Journal of Clinical Medicine (2020)
8. Prognostic Significance of Baseline Clinical and [68Ga]Ga-Psma Pet Derived Parameters on Biochemical Response, Overall Survival, and Psa Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients Undergoing [177Lu]Lu-Psma Therapy, Nuklearmedizin - NuclearMedicine (2024)
Experts (# of related papers)
View all Related Experts
Reyhaneh Manafi-Farid (4)
Nasim Vahidfar (2)